eXoZymes (EXOZ) investor relations material

Technology and platform

• Developed a cell-free, AI-enhanced biomanufacturing platform enabling scalable, high-purity production of rare and novel natural products.

• Platform bypasses traditional cell-based bottlenecks, delivering 100x scale-up and >99% purity, validated by third parties.

• Enables rapid prototyping to commercialization in months, not years, at a fraction of traditional biotech costs.

• AI-enzyme engineering accelerates product development and expands the range of manufacturable molecules.

Product pipeline and market opportunity

• Focused on two flagship programs: NCT (metabolic health) and rare cannabinoids, each targeting $100B+ TAM.

• NCT: Achieved 99.6% pharma-grade purity at 100x scale; addresses metabolic health, gut, and liver function.

• Cannabinoids: Producing rare, non-intoxicating molecules at GMP purity, overcoming previous manufacturing barriers.

• Both programs have dual OTC nutraceutical and pharmaceutical commercialization paths.

Commercialization and go-to-market strategy

• Delivers validated biomanufacturing systems to partners, retaining platform IP.

• Commercialization via tech transfer, contract manufacturing, licensing, JVs, and spinouts.

• Value captured through equity, royalties, and licensing agreements.